Mitochondria-targeted drugs can also synergize with immune checkpoint blockade therapy by reversing tumor hypoxia, inhibiting PD-L1 expression, or inducing ICD, reversing immunosuppression TME, and reducing tumor necrosis factor-α expression, enhance the effect of photodynamic immunotherapy, enhance T cell lytic activity, and then enhance tumor immunity. The gene discussed is CD274; the disease is neoplasm.